Salih N Karahan, Mustafa Oruc, Kamil Erozkan, Michael Valente, Anuradha Bhama, Scott Steele, Hermann Kessler, David Liska, Emre Gorgun
{"title":"Optimal Timing for Rectal Cancer Surgery After Total Neoadjuvant Therapy: When Does Surgery Get Really Challenging?","authors":"Salih N Karahan, Mustafa Oruc, Kamil Erozkan, Michael Valente, Anuradha Bhama, Scott Steele, Hermann Kessler, David Liska, Emre Gorgun","doi":"10.1097/DCR.0000000000003940","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Total neoadjuvant therapy is increasingly utilized for locally advanced rectal cancer. However, the optimal interval between total neoadjuvant therapy and surgery remains unclear. Existing trials report intervals ranging from 2-4 weeks to 11-18 weeks, and many surgeons believe surgery becomes more difficult after a certain point, but the exact timing and its impact on complications are unknown.</p><p><strong>Objective: </strong>To identify the time point after total neoadjuvant therapy when surgery becomes more challenging and define an optimal window for minimizing postoperative complications in patients proceeding directly to resection.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Settings: </strong>Single tertiary care center.</p><p><strong>Patients: </strong>Patients with locally advanced rectal cancer who completed total neoadjuvant therapy between 2015 and 2023 and underwent surgery due to primary disease or regrowth during a watch-and-wait strategy.</p><p><strong>Intervention: </strong>Total neoadjuvant therapy followed by surgery.</p><p><strong>Main outcome measures: </strong>The primary outcome was the association of time from total neoadjuvant therapy completion to surgery with postoperative complication rates. Secondary outcomes included perioperative and postoperative outcomes.</p><p><strong>Results: </strong>Among 212 patients (median age 57 [IQR 50-66], 59% male), 42% experienced complications (15% Clavien-Dindo ≥3). Restricted cubic spline analysis suggested a dip in overall morbidity around 7-12 weeks, with increased risk beyond 24 weeks. Patients operated ≥24 weeks (n = 29) had higher rates of margin positivity (17% vs. 3%, p < 0.01), reoperations (21% vs. 8%, p = 0.04), and severe complications (28% vs. 13%, p = 0.03) compared to those operated earlier (n = 183).</p><p><strong>Limitations: </strong>Single-center retrospective design, univariate spline analysis, and a relatively small subset beyond 24 weeks limit the generalizability.</p><p><strong>Conclusion: </strong>Surgical timing after total neoadjuvant therapy is associated with perioperative outcomes. Delaying surgery beyond 24 weeks is linked to greater surgical difficulty and morbidity. Further multicenter studies are needed to confirm these findings and refine timing recommendations. See Video Abstract.</p>","PeriodicalId":11299,"journal":{"name":"Diseases of the Colon & Rectum","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases of the Colon & Rectum","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DCR.0000000000003940","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Total neoadjuvant therapy is increasingly utilized for locally advanced rectal cancer. However, the optimal interval between total neoadjuvant therapy and surgery remains unclear. Existing trials report intervals ranging from 2-4 weeks to 11-18 weeks, and many surgeons believe surgery becomes more difficult after a certain point, but the exact timing and its impact on complications are unknown.
Objective: To identify the time point after total neoadjuvant therapy when surgery becomes more challenging and define an optimal window for minimizing postoperative complications in patients proceeding directly to resection.
Design: Retrospective cohort study.
Settings: Single tertiary care center.
Patients: Patients with locally advanced rectal cancer who completed total neoadjuvant therapy between 2015 and 2023 and underwent surgery due to primary disease or regrowth during a watch-and-wait strategy.
Intervention: Total neoadjuvant therapy followed by surgery.
Main outcome measures: The primary outcome was the association of time from total neoadjuvant therapy completion to surgery with postoperative complication rates. Secondary outcomes included perioperative and postoperative outcomes.
Results: Among 212 patients (median age 57 [IQR 50-66], 59% male), 42% experienced complications (15% Clavien-Dindo ≥3). Restricted cubic spline analysis suggested a dip in overall morbidity around 7-12 weeks, with increased risk beyond 24 weeks. Patients operated ≥24 weeks (n = 29) had higher rates of margin positivity (17% vs. 3%, p < 0.01), reoperations (21% vs. 8%, p = 0.04), and severe complications (28% vs. 13%, p = 0.03) compared to those operated earlier (n = 183).
Limitations: Single-center retrospective design, univariate spline analysis, and a relatively small subset beyond 24 weeks limit the generalizability.
Conclusion: Surgical timing after total neoadjuvant therapy is associated with perioperative outcomes. Delaying surgery beyond 24 weeks is linked to greater surgical difficulty and morbidity. Further multicenter studies are needed to confirm these findings and refine timing recommendations. See Video Abstract.
背景:全新辅助治疗越来越多地用于局部晚期直肠癌。然而,完全新辅助治疗和手术之间的最佳时间间隔仍不清楚。现有的试验报告的间隔从2-4周到11-18周不等,许多外科医生认为,在某个时间点之后,手术会变得更加困难,但确切的时间和它对并发症的影响尚不清楚。目的:确定手术变得更具挑战性的全新辅助治疗后的时间点,并确定一个最佳窗口,以尽量减少患者直接进行切除的术后并发症。设计:回顾性队列研究。设置:单一三级保健中心。患者:在2015年至2023年间完成全部新辅助治疗并因原发疾病或在观察等待策略期间再生而接受手术的局部晚期直肠癌患者。干预措施:手术后全新辅助治疗。主要结局指标:主要结局是从新辅助治疗完成到手术的时间与术后并发症发生率的关系。次要结局包括围手术期和术后结局。结果:212例患者(中位年龄57岁[IQR 50-66], 59%男性),42%出现并发症(15% Clavien-Dindo≥3)。限制性三次样条分析表明,总发病率在7-12周左右下降,超过24周的风险增加。手术≥24周的患者(n = 29)的切缘阳性率(17% vs. 3%, p < 0.01)、再手术率(21% vs. 8%, p = 0.04)和严重并发症率(28% vs. 13%, p = 0.03)高于较早手术的患者(n = 183)。局限性:单中心回顾性设计、单变量样条分析和超过24周的相对较小的子集限制了通用性。结论:全新辅助治疗后手术时机与围手术期预后相关。延迟手术超过24周会增加手术难度和发病率。需要进一步的多中心研究来证实这些发现并完善时间建议。参见视频摘要。
期刊介绍:
Diseases of the Colon & Rectum (DCR) is the official journal of the American Society of Colon and Rectal Surgeons (ASCRS) dedicated to advancing the knowledge of intestinal disorders by providing a forum for communication amongst their members. The journal features timely editorials, original contributions and technical notes.